Human Cdc34 is an ubiquitin conjugating enzyme or E2 that ubiquitinates substrates including p27 Kip1 , IκBα, Wee1 and MyoD. Cdc34 possesses a core catalytic domain encoding the active site cysteine and an acidic tail domain within the carboxyl terminal 36 amino acids. Studies suggest that Cdc34 is phosphorylated in mammalian cells at 5 potential residues within the tail domain. In order to study the biological significance of the Cdc34 acidic tail domain and the possible significance of phosphorylation within this region, we tested the ability of human Cdc34 mutants to complement the cdc34-2 temperature sensitive (ts) strain of Saccharomyces cerevisiae. Our studies indicated that complementation of the cdc34-2 ts strain was critically dependent upon the carboxylterminal 36 amino acids of human Cdc34, but did not require phosphorylation of human Cdc34 residues S203, S222, S231, T233, and S236. Further studies demonstrated that although a Cdc34 mutant bearing a deletion of the C-terminal 36 amino acids (Cdc34
INTRODUCTION
Eukaryotic cells require ubiquitin-mediated protein degradation to maintain proper cell cycle progression and homeostasis. 1, 2 The regulated polyubiquitination of a substrate protein is dependent upon an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme (E2 or UBC), and often, an ubiquitin protein ligase (E3). 3 Cdc34 is an ubiquitin conjugating enzyme (UBC3) that is required for the G 1 to S phase transition in Saccharomyces cerevisae and the initiation of DNA replication in Xenopus laevis interphase egg extracts. [4] [5] [6] Studies in budding yeast have demonstrated that the human CDC34 gene can functionally complement a cdc34 temperature sensitive (ts) strain at the non-permissive temperature. 7 Structurally, human Cdc34 is comprised of an amino-terminal catalytic domain encoding the active site cysteine and a carboxyl-terminal acidic tail domain. In both budding yeast and in mammals, Cdc34 has been shown to function in association with the E3 called SCF. 8 The SCF is comprised of an F-box binding protein called Skp1, an F-box protein which binds the substrate, a cullin protein which serves as a scaffold, and a RING finger protein called Roc1/Rbx1/Hrt1 which helps to recruit the E2. [8] [9] [10] Cdc34 and SCF Skp2 have been shown to mediate the in vitro polyubiquitination of the mammalian cyclin-dependent kinase (CDK) inhibitor, p27 Kip1 . [11] [12] [13] [14] The modeled three dimensional crystal structure of the human SCF Skp2 complex suggests that Cul1 and Roc1 recruit the E2 and position its active site cysteine optimally for ubiquitin transfer to the Skp2-bound substrate. 10 In addition, past studies have indicated that residues 195-208 of human Cdc34 were required for a stable interaction with Cul-Roc1, while residues 209-236 enhanced this interaction significantly and were required for maximal binding to Cul1-Roc1. 15 These results were based on in vitro binding studies of human Cdc34 with Cul1-Roc1 and on in vitro substrate-independent polyubiquitin chain assembly (or Cdc34 auto-ubiquitination) studies. 15 Recent studies in budding yeast have also demonstrated that the critical step in the ubiquitination of the yeast CDK inhibitor, p40 Sic1 , is actually the efficient dissociation of yeast Cdc34p from SCF Cdc4 . 16 These studies indicated that both charged and uncharged Cdc34p efficiently associated with the SCF, but only charged Cdc34p efficiently dissociated from the SCF and supported the ubiquitination of p40 Sic1 . 16 Our past studies have suggested that human Cdc34 is a phosphoprotein in mammalian cells that is phosphorylated by Casein Kinase 2 (CK2). 17 CK2 is a constitutive serine-threonine kinase that is essential for cell cycle progression in both budding yeast and mammalian cells. [18] [19] [20] [21] [22] The in vivo phosphorylation sites of human Cdc34 are localized within the carboxyl-terminal 36 amino acids at five potential CK2 consensus sites (S203, S222, S231, T233, S236). 17 Alanine mutation of these five residues eliminated all in vivo phosphorylation of Cdc34 in mammalian cells and shifted the cellular localization of Cdc34 from the nucleus to the cytoplasm. 17 This suggested that Cdc34 phosphorylation by CK2 might play a role in modulating Cdc34 cell localization and function. Previous studies have demonstrated a role for CK2-mediated phosphorylation in promoting the nuclear localization of SV-40 large T antigen. 23 Presumably, the phosphorylation status of human Cdc34 may alter its association with proteins that regulate the subcellular localization of Cdc34. The subcellular localization of Cdc34 is normally predominantly nuclear, but the Cdc34 primary sequence does not reveal any obvious nuclear localization sequence consensus sites. 17 Although the residues phosphorylated in human Cdc34 are not conserved in budding yeast Cdc34p, we wanted to address whether phosphorylation of C-terminal residues within human Cdc34 or the acidic tail domain in general are required for complementation of a cdc34 ts budding yeast strain. Our results demonstrate that while phosphorylation at five CK2 consensus sites appears to be dispensable, the carboxyl-terminal 36 amino acids of human Cdc34 are essential for complementation of a cdc34-2-ts budding yeast strain. Importantly, this acidic tail domain of Cdc34 is also required for the efficient in vitro ubiquitination of p27 Kip1 by SCF Skp2 . In order to understand the defect of Cdc34 bearing a deletion of the carboxyl-terminal 36 amino acids (1-200), we examined its ability to be charged by E1 and to bind the SCF. Our results demonstrate that the Cdc34 1-200 mutant is charged by E1, and contrary to past studies, also efficiently interacts with the SCF components, Cul1 and Roc1, both in vivo and in vitro. This suggests that the ubiquitination defect of human Cdc34 deleted of the C-terminal tail domain functionally lies after its association with the SCF. We postulate that the C-terminal 36 amino acids of human Cdc34 may be required for its efficient dissociation from the SCF or may instead be more directly required for the transfer of ubiquitin from Cdc34 to the substrate.
MATERIALS AND METHODS
Cell culture, transfection and preparation of whole-cell extracts. Human osteosarcoma U2OS cells (American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units/ml of penicillin and 50 ug/ml streptomycin sulfate at 37˚C with 5% CO 2 . Cells were transiently cotransfected with either pCS2+/2HA-Cdc34 or pCS2+/ 2HA-Cdc34(1-200) as well as pcDNA3.1/Cul1-HA and pCS2+/Myc-Roc1 using the N,N-bis(2-hydroxyethyl)-2-amino-ethanesulfonic acid (BES)-based calcium phosphate precipitation method as previously described. 17 Forty hours post-transfection, untransfected or transfected whole-cell extracts were prepared as described previously. 24 Briefly, cells were resuspended in ice-cold NETN buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris-HCl pH 7.5, and 0.1 % NP40) supplemented with protease inhibitor cocktail (Sigma), and then subjected to three freeze/thaw cycles. Insoluble debris was removed by centrifugation at 14,000 x g for 15 min at 4˚C. Total protein concentrations were determined by Bradford assay (Bio-Rad).
Plasmid construction. Cdc34 WT and Cdc34 mutants were cloned into pQE30 (Qiagen) for bacterial expression of amino-terminally tagged proteins as previously described. 6, 17 pCS2+/Myc-Roc1 was generated by subcloning a BamHI-XbaI Myc-tagged Roc1 fragment into pCS2+. pcDNA3.1/ Cul1-HA was a generous gift from A. Pause.
Recombinant protein expression and purification. Hexahistidinetagged proteins were expressed from pQE30 and purified using Nickelnitrilotriacedic acid Sepharose according to manufacturer's instructions (Qiagen) as previously described and were extensively dialyzed into 1X PBS before use in binding assays. 6, 17 Purified SCF Skp2 and CDK2-cyclin E were generated as previously described. 12, 14, 25 E2 charging reaction. The reaction mixture contained the following in a volume of 10 µl: 50 mM Tris-HCl pH 7.6, 5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 0.5 mM ATP, 5 µM biotinylated ubiquitin, 100 ng E1 and 500 ng Cdc34 (wildtype or mutants). After incubation at 37˚C for 0, 15, 30 or 60 minutes, the reaction was stopped by the addition of sample buffer without β-mercaptoethanol. Samples were subjected to SDS-PAGE and analyzed by immunoblotting with Horseradish Peroxidase (HRP)-streptavidin.
p27 ubiquitination assay. The reaction mixture contained the following in a volume of 10 µl: 40 mM Tris-HCl pH 7.6, 5 mM MgCl 2 , 1 mM DTT, 10% (v/v) glycerol, 2 µg/µl BSA, 10 mM phosphocreatine, 100 µg/µl creatine phosphokinase, 0.5 mM ATP, 1 µM ubiquitin aldehyde, 1 mg/ml methylated ubiquitin, 10 ng/µl E1, 150 ng/µl Cdc34 WT or mutants, 20 ng/µl SCF Skp2 , 4 ng/µl CDK2-cyclin E, and 0.3 µl [ 35 S]-p27 as described. 25 After incubation at 30°C for 0, 15, 30, or 60 minutes, samples were subjected to SDS-PAGE and autoradiography.
Antibodies, immunoblotting, in vitro co-immunoprecipitation assay, and immunoprecipitation (IP)-Western assay. Anti-Cdc34 antibody was generated as previously described and used following affinity purification for immunoblotting at a final concentration of 1.2 µg/ml. 6 Immunoblots were performed as previously described. 17 In vitro co-immunoprecipitation assay: In a 20 µl reaction volume, 5 µl of cotranslated [ 35 S]-methionine-labeled HA-Cul1/Roc1 (NEN, TNT Quick Coupled Kit, Promega) was added to 2.5 µg of recombinant 6xHis-tagged Cdc34 protein. Samples were allowed to bind at 30˚C for 1 hr followed by a preclearing step with 20 µl protein A-sepharose CL-4B beads (Amersham Biosciences). The lysates were then immunoprecipitated with 2 µl anti-Cdc34 rabbit serum or normal rabbit serum (NRS) (Sigma) and 25 µl protein A sepharose beads. After incubation, the protein A sepharose beads were washed with RIPA buffer (100 mM Tris-Cl pH 8, 10 mM EDTA, 150 mM NaCl, 1% Nonidet P-40), the beads were aspirated and boiled in 1X sample buffer, and the samples were resolved by SDS-PAGE. Five percent (1/20 th ) of the input [ 35 S]-labeled protein was included on the gel to aid in the quantitation of the bound fractions. Quantitation of the bound fractions was determined by Phosphorimager analysis using ImageQuant software (Molecular Dynamics). Background binding (binding to beads immunoprecipitated with NRS) was subtracted from the values for the bound fractions. The percentage of Cdc34 bound to Cul1 and Roc1 was then determined based on the 5% input value for Cul1 and Roc1. These values ranged between 0.76%-1.63% binding of WT Cdc34 to Cul1 and 0.42%-0.9% binding of WT Cdc34 to Roc1. The binding for WT Cdc34 was then normalized to 100% and the binding for the mutant Cdc34 samples was normalized relative to the WT Cdc34. The Standard Error of the Mean was then calculated for each set of samples and was included as error bars on the graph in Figure 3B . The recovery of equivalent amounts of Cdc34 protein (WT or mutants) was confirmed by examining a fraction of the total sample by coomassie blue staining. Data was used only from experiments where the Cdc34 samples were recovered equivalently. In Figure 3B Complementation studies in Saccharomyces cerevisiae and extract preparation. The human CDC34 wildtype and mutants were cloned into pSF315B, a derivative of pRS315 for complementation studies using two different cdc34-2 temperature sensitive strains which gave similar results: SJ1098-3d (MATa cdc34-2 leu2-3 ura3 trp1), a generous gift from S. Plon and B. Byers, and L6204 (MATa cdc34-2 leu2^2 ura3-52 gcn4^1 ade8-GCN4), a generous gift from G. Fink. 26 pSF315B plasmids were transformed into yeast strains using lithium acetate and then were analyzed for growth at 24˚C, 30˚C and 37˚C on leucine-minus minimal plates supplemented with galactose (L6204) or galactose and raffinose (SJ1098-3d) as described. 27 For extract preparation, cells were collected by centrifugation, washed in water, and lysed using lysis buffer containing 50 mM NaOH, 2% SDS, 10% glycerol, 5% β-mercaptoethanol. After vortexing, the samples were boiled, titrated to pH 7.0 using HCl, and centrifuged at 14K rpm for 5 min.
RESULTS
The carboxyl-terminal 36 amino acids of human Cdc34 are essential for complementation of a temperature sensitive budding yeast strain. Cdc34 protein from budding yeast and humans share ~41% amino acid identity with the highest homology exhibited within the amino-terminal catalytic domain surrounding the active site cysteine residue. Although little homology is observed in the carboxyl-terminal domains of yeast and human Cdc34, both proteins exhibit highly acidic tails. Our past studies suggest that human Cdc34 is phosphorylated in vivo by CK2 at five possible residues (S203, S222, S231, T233, and S236). 17 When these five residues of Cdc34 are mutated to alanine and examined in vivo, the subcellular localization of Cdc34 is shifted from the nucleus to the cytoplasm. 17 In order to determine the role of the acidic tail domain of human Cdc34 and the possible role of phosphorylation within this domain, we tested the ability of several human Cdc34 mutants to complement the budding yeast ts strain, cdc34-2. Wildtype human Cdc34 (1-236), C-terminal truncation mutant 1-200, and point mutants disrupted at putative CK2 phosphorylation sites within the carboxyl-terminal domain by alanine mutation (three point mutant or 3 PT MUT: S231A, T233A, S236A and five point mutant or 5 PT MUT: S203A, S222A, S231A, T233A, S236A) were cloned into the yeast expression vector, pSF315B (Fig. 1A) . At the nonpermissive temperature of 37°C, wildtype human Cdc34 complemented the growth defect of the cdc34-2 ts strain as expected, while the active-site point mutant, CL-S (C93S, L97S), did not (Fig. 1B) . In contrast to wildtype Cdc34, the Cdc34 1-200 truncation mutant was completely defective for complementation of the cdc34-2 ts strain, while the Cdc34 3 PT MUT and 5 PT MUT complemented the cdc34-2 ts strain to similar extents as wildtype (Fig. 1B) . Immunoblot analysis demonstrated that the human Cdc34 wildtype and 1-200 proteins were expressed in the cdc34-2 ts strain to similar levels indicating that the inability of the human Cdc34 1-200 to complement the cdc34-2 ts strain was not merely due to an instability of the human 1-200 protein in yeast (Fig. 1C) . This result demonstrates that the acidic tail domain of human Cdc34 is critical for its complementation function in yeast, while alanine mutation of human Cdc34 at residues 203, 222, 231, 233 and 236 does not disrupt the complementation function of human Cdc34. Because sequences within the tail domain of budding yeast Cdc34p have been shown to be important for its association with the SCF, we postulate that the human Cdc34 1-200 mutant may be compromised in its ability to associate with the yeast SCF to mediate the ubiquitination of p40 Sic1 . 28 The human Cdc34 truncation mutant, 1-200, is charged by E1. One trivial explanation for the inability of the human Cdc34 1-200 to complement the budding yeast cdc34-2 ts strain is that this mutant may not be efficiently charged with ubiquitin by E1 compared to the wildtype protein.
Previous studies have indicated that the acidic tail domain of human Cdc34 is not required for charging by E1, but to directly examine this possibility, we measured the efficiency of E1 and ATP to charge recombinant wildtype and mutant human Cdc34 proteins in a thiolester assay. 15 The results demonstrated that wildtype Cdc34, the A C B charged in the presence of E1 (Fig. 2A) . This indicates that the defect of the Cdc34 1-200 mutant did not lie in its ability to be charged by E1. The C-terminal 36 amino acids of Cdc34 are required for the ubiquitination of p27 Kip1 . The inability of the human Cdc34 1-200 mutant to complement a budding yeast ts strain indicated that the carboxyl-terminal 36 amino acids of Cdc34 were critical for its ubiquitination function. Instead of pursuing the defect of the human Cdc34 1-200 mutant in yeast, we wanted to determine whether this Cdc34 mutant could support the ubiquitination of a known human substrate. In mammalian cells, the CDK inhibitor protein, p27 Kip1 , inhibits CDK2-cyclins during the G 1 to S phase transition. [29] [30] [31] Before the onset of S phase, p27 Kip1 is targeted for ubiquitination and degradation by the ubiquitination machinery, Cdc34 and the SCF Skp2 . 11, 14, 32 The polyubiquitination of p27 Kip1 is dependent upon p27 Kip1 phosphorylation on threonine 187 by CDK2-cyclin E and subsequent binding to the F-box protein, Skp2. 12, [32] [33] [34] [35] To further study the role of the Cdc34 acidic tail domain, we tested the ability of wildtype and mutant Cdc34 proteins to ubiquitinate p27 Kip1 in vitro in the presence of SCF Skp2 . For these studies, we examined the function of the Cdc34 truncation mutant missing the C-terminal 36 amino acids (1-200), as well as two point mutants at CK2 consensus phosphorylation sites (5 PT MUT A: S203A, S222A, S231A, T233A, S236A bearing alanine mutations to prevent phosphorylation, and 5 PT MUT E: S203E, S222E, S231E, T233E, S236E bearing glutamic acid mutations to mimic constitutive phosphorylation). 17 Using a reconstituted in vitro ubiquitination assay, our studies indicated that while the WT, 5 PT MUT A, and 5 PT MUT E Cdc34 proteins all supported p27 Kip1 ubiquitination, the Cdc34 1-200 truncation mutant was significantly reduced for the ability to ubiquitinate p27 Kip1 (Fig. 2B) . Under the conditions used, the phosphorylation status of WT Cdc34 is unclear because although no CK2 was added to the assay, CK2 activity able to phosphorylate recombinant Cdc34 is present in rabbit reticulocyte lysate which is used in the assay to in vitro transcribe and translate p27 Kip1 (data not shown). Nevertheless, the Cdc34 5 PT MUT A will not be phosphorylated, while the Cdc34 5 PT MUT E will partially mimic the negative charge of phosphorylation at these residues. The result suggests that the carboxyl-terminal 36 amino acids of human Cdc34 are critical for its ubiquitination function, but possible phosphorylation of serine and threonine residues within the acidic tail domain of Cdc34 at five potential CK2 sites is not required for, and does not appear to enhance, the ubiquitination of p27 Kip1 in vitro.
The C-terminal 36 amino acids of Cdc34 are dispensable for efficient binding to the SCF components, Cul1 and Roc1. In vitro binding studies of Cdc34 with Cul1 and Roc1 and Cdc34 auto-ubiquitination assays suggest that Cdc34 is recruited to the SCF through an interaction with a Cul1-Roc1 heterodimer. 15, 36 More specifically, in vitro binding studies indicate that residues 195-236 of Cdc34 are required for maximal binding to GST-Roc1-Cul1 . 15 This suggested to us that the Cdc34 1-200 defect in complementation and p27 Kip1 ubiquitination might be attributable to an inability of the truncated Cdc34 to bind efficiently to the SCF through its association with Cul1-Roc1.
To study the binding efficiency of the Cdc34 1-200 mutant with Cul1 and Roc1, an in vitro binding assay was employed. Recombinant wildtype and mutant (1-200, 5 PT MUT A, and 5 PT MUT E) Cdc34 proteins (Fig.  3C, left panel) were incubated with cotranslated 35 S-labeled Cul1 and Roc1 (Fig. 3C, right panel) . The samples were then immunoprecipitated with anti-Cdc34 antibody and the coprecipitated Cul1 and Roc1 were quantitated by Phosphorimager analysis. The binding results indicated that the Cdc34 1-200 mutant bound to Cul1 and Roc1 at a level similar to the WT Cdc34 protein, suggesting that the C-terminal 36 amino acids of Cdc34 containing acidic residues and the CK2 phosphorylation sites are not required for in vitro binding to Cul1 and Roc1 (Fig. 3A, B) . This is contrary to published studies of Cdc34 binding to Cul1 and Roc1. 15 Paradoxically, the binding of the Cdc34 5 PT MUT A to Cul1 and Roc1 was reduced compared to WT Cdc34 and the Cdc34 1-200 mutant, while the binding of the Cdc34 5 PT MUT E to Cul1 and Roc1 was similar to WT Cdc34 (Fig. 3A, B) . Based on our unpublished observations, it is likely that the recombinant WT Cdc34 protein is phosphorylated to some extent by the reticulocyte lysate used in the binding assay. However, it is unclear to what extent the Cdc34 protein may be phosphorylated. Supplementing the binding assay with recombinant CK2 did not appear to alter the binding of WT Cdc34 to Cul1 and Roc1 (data not shown). Therefore, we were not able to fully determine how phosphorylation of Cdc34 may affect its association to Cul1 and Roc1, but based on the result with the Cdc34 1-200 mutant, phosphorylation within the C-terminal tail domain of Cdc34 is not required for Cul1 or Roc1 binding. We postulate that alanine mutation of residues in the Cdc34 5 PT MUT A within the Cdc34 C-terminus may alter the inherent structure of Cdc34 and inhibit its binding to Cul1 and Roc1.
The discrepancy between our studies and previous studies may be due to several different factors. In previous studies, Wu et al. studied direct binding of recombinant Cdc34 to a heterodimer containing full-length recombinant Roc1 and a truncated form of Cul1 (amino acids 324-776). 15 In our studies, we use full-length Roc1 and Cul1 provided as an in vitro translation and A B therefore we cannot rule out the presence of other proteins from the reticulocyte lysate which may influence binding. To understand the Cdc34 requirements for Cul1 and Roc1 binding under more physiological conditions, we studied the binding of the WT and 1-200 Cdc34 proteins to Cul1 and Roc1 in mammalian cells. We cotransfected human U2OS cells with HAtagged WT Cdc34 or mutant Cdc34 1-200 along with HA-tagged Cul1 and Myc-tagged Roc1. We then immunoprecipitated the transfected Roc1 using anti-Myc agarose beads and analyzed the beads for coprecipitated Cul1 and Cdc34 proteins by western blotting with anti-HA antibody (Fig.  4, right panel, lanes 5 and 6) . The results indicated that equivalent amounts of WT and 1-200 Cdc34 proteins were coprecipitated with Cul1 and Roc1, suggesting that the C-terminal 36 amino acids of Cdc34 are not required for efficient in vivo binding to Cul1 and Roc1. These studies further indicate that the defect in the function of Cdc34 1-200 in complementing the budding yeast ts strain or in the ubiquitination of p27 Kip1 does not lie in its association with the SCF, but instead appears to lie in a step following the association of the SCF with Cdc34.
DISCUSSION
Our studies address the role ofºast cdc34 ts strain, to ubiquitinate p27 Kip1 , and to associate with the SCF components, Cul1 and Roc1. Our studies demonstrated that the C-terminal 36 amino acids were critical for complementation of a cdc34 budding yeast ts strain and for the in vitro ubiquitination of p27 Kip1 by Cdc34-SCF Skp2 . In contrast, phosphorylation within the C-terminal 36 amino acids of Cdc34 at 5 potential CK2 sites was dispensable for complementation and p27 Kip1 ubiquitination. Contrary to past studies, our results indicated that the C-terminal 36 amino acids of Cdc34 were not required for efficient in vitro or in vivo binding of Cdc34 to the SCF components, Cul1 and Roc1, suggesting that the defect of the Cdc34 C-terminal truncation mutant called 1-200 lay in steps following the association of Cdc34 with the SCF. 15 In budding yeast, studies have demonstrated that ubiquitin charging of Cdc34p is critical for its dissociation from the SCF Cdc4 which in turn is essential for efficient ubiquitination of p40 Sic1 . 16 Although no studies have been performed to study a requirement for dissociation from the SCF for the ubiquitination function of human Cdc34, it is predicted that human Cdc34 may function in a manner similar to budding yeast Cdc34p. We have shown that the C-terminal 36 amino acids of human Cdc34 are not required for ubiquitin charging by E1, a result that is consistent with previous findings. 15 Our results also indicate that the C-terminal 36 amino acids of Cdc34 are not required for the association of Cdc34 with Cul1 and Roc1, both in vivo and in vitro. Therefore, given the significant reduction in the ability of the Cdc34 mutant, 1-200, to ubiquitinate p27 Kip1 compared to WT Cdc34, we postulate that the C-terminal 36 amino acids of Cdc34 may be important for the efficient dissociation of human Cdc34 from the SCF. Current studies are being conducted to address this possibility. If the tail domain of human Cdc34 is not found to be required for its efficient dissociation from the SCF, then this may indicate that the C-terminal 36 amino acids of Cdc34 may instead play an important direct role in ubiquitin transfer to the substrate. It is possible that the acidic C-terminal residues of Cdc34 contact the basic lysine residues of the substrate and form a transient association that is important for proper ubiquitin transfer to the substrate. Because we have not studied the ubiquitination of other Cdc34 substrates, we cannot exclude the possibility that the defect of the Cdc34 1-200 mutant may be specific to only p27 Kip1 , but we predict that the defect of Cdc34 1-200 will be generally observed with other Cdc34 substrates.
Studies have indicated that residues 171 to 244 within the tail domain of budding yeast Cdc34p are important for the cell cycle function of Cdc34p, while residues 171 to 209 are necessary and sufficient for Cdc34p binding to the yeast SCF. 28, [37] [38] [39] Our studies demonstrate that residues 201 to 236 within the tail domain of human Cdc34 are required to complement the cell cycle function of the budding yeast cdc34 ts mutant strain. Although the tail domain of human Cdc34 is significantly shorter than the yeast Cdc34p tail domain and no amino acid sequence homology exists between the Cdc34 tail domains in yeast and humans, structural elements must mutant to complement the cell cycle defect of the cdc34 ts strain suggests a failure of the human Cdc34 mutant to mediate the ubiquitination and degradation of the critical substrate of Cdc34 in yeast, the CDK inhibitor p40 Sic1 . [40] [41] [42] [43] [44] It is also possible that the human Cdc34 1-200 mutant may efficiently bind to the yeast SCF Cdc4 , but may instead be defective in another step such as release from the yeast SCF.
Studies by Wu et al. have indicated that residues 170-194 of human Cdc34 are important for catalyzing the auto-ubiquitination of Cdc34 in the presence of E1 and that residues 209 to 236 are necessary for the formation of Roc1-Cul1-dependent ubiquitin polymers. 15 A Cdc34 mutant (1-208) could mediate the assembly of multi-ubiquitin chains, but at an efficiency 100 fold lower than wildtype Cdc34, while residues 195-208 of Cdc34 were essential for the generation of extensive Roc1-Cul1 polyubiquitin chains. 15 Our studies measured the ubiquitination of p27 Kip1 , a physiological substrate of human Cdc34, in the presence of E1, Cdc34, and the SCF Skp2 , rather than examining the formation of polyubiquitin chains mediated by E1, Cdc34, and only the Roc1-Cul1 components of the SCF. Binding studies by Wu et al. suggested that residues 195 to 208 of human Cdc34 play a critical role in the association of Cdc34 with Roc1-Cul1 and that residues 209 to 236 of Cdc34 were required for optimal binding efficiency to the SCF. 15 Our studies indicated that removal of the C-terminal 36 amino acids of Cdc34 in the 1-200 mutant did not significantly influence the ability of Cdc34 to associate with Roc1-Cul1 in vitro, nor did it affect the binding of Cdc34 to the SCF in vivo. The differences observed in Cdc34 enzymatic function between our studies and the studies of Wu et al. are most likely attributable to our study of substrate ubiquitination versus the study of ubiquitin polymer formation by Wu et al. The differences in Cdc34 binding to the SCF are most likely due to differences in the binding assay conditions used. While Wu et al. used a truncated Cul1 (aa 324-776) we used full-length Cul1. 15 Additionally, Wu et al. used exclusively bacterially expressed and purified proteins while our assay utilized in vitro translated Roc1-Cul1. We also conducted in vivo binding studies between ectopically expressed Cdc34 and Roc1-Cul1 in the presence of endogenous SCF components. In general, our studies attempted to examine the interaction of the Cdc34 1-200 truncation mutant with the SCF under more physiological conditions compared to the binding studies of Wu et al.
Our studies indicate that phosphorylation of human Cdc34 at residues S203, S222, S231, T233 and S236 in budding yeast is not required for complementation of the cdc34 ts strain. Although our in vitro binding study and p27 Kip1 ubiquitination assay were not performed in the presence of CK2, our unpublished results indicate that CK2 activity appears to be present in rabbit reticulocyte lysate which was included in both assays. Because of this, we do not know the exact status of Cdc34 phosphorylation within these experiments. However, the ability of the Cdc34 5 PT MUT A to mediate the ubiquitination of p27 Kip1 at a level comparable to WT Cdc34 suggests that Cdc34 phosphorylation is not essential for p27 Kip1 ubiquitination in vitro. Whether CK2 phosphorylation of Cdc34 may promote the binding of Cdc34 to the SCF and contribute to the nuclear localization of Cdc34 in vivo is still unclear. Our studies were conducted using in vitro assays which could not address the possible effects of phosphorylation on the subcellular localization of Cdc34. We have attempted to study the possible biological function of Cdc34 phosphorylation on the mammalian cell cycle by overexpressing the Cdc34 5 PT MUT A in mammalian cells. While we observed that this mutant significantly inhibited the entry of cells into S phase, we also observed a similar effect on cell cycle progression upon the overexpression of wildtype Cdc34 and other non-phosphorylation mutants of Cdc34. Future studies will be required to understand the potential biological significance of phosphorylation on Cdc34 function.
